Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules

Bioconjugate Chemistry

Volumn 22, Issue 5, 2011, Pages 894-902

  Tolmachev, Vladimir ^a   Altai, Mohamed ^a   Sandström, Mattias ^b   Perols, Anna ^c   Karlström, Amelie Eriksson ^c   Boschetti, Frederic ^d   Orlova, Anna ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^d CheMatech   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL CULTURE; DISEASES; DISSOCIATION; MOLECULAR IMAGING; MOLECULES; PATIENT TREATMENT; RADIOISOTOPES;

AFFIBODY MOLECULES; DISSOCIATION CONSTANT; HIGH AFFINITY; IMAGING PROBE; LABELINGS; PET IMAGING; SITE-SPECIFIC; SPECT IMAGING; STABLE COMPLEXES; TERMINAL CYSTEINE;

TUMORS;

CHELATING AGENT; CYSTEINE; INDIUM 111; MALEIMIDE DERIVATIVE; MALEIMIDOETHYLMONOAMIDE 2,2',2'' (1,4,7 TRIAZACYCLONONANE 1,4,7 TRIYL)TRIACETIC ACID INDIUM IN 111; UNCLASSIFIED DRUG;

AFFINITY LABELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROSTATE CANCER; SCINTILLATION CAMERA; TUMOR XENOGRAFT;

MUS;

EID: 79959574104     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc100470x     Document Type: Article

References (48)

1. Mankoff, D. A. (2009) Molecular imaging to select cancer therapy and evaluate treatment response. Q. J. Nucl. Med. Mol. Imaging 53, 181-192.
2. Tolmachev, V., Stone-Elander, S., and Orlova, A. (2010) Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol. 11, 992-1000.
3. Grönwall, C., and Ståhl, S. (2009) Engineered affinity proteins -generation and applications. J. Biotechnol. 140, 254-269.
4. Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., and Frejd, F. Y. (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 584, 2670-2680.
5. Ahlgren, S., and Tolmachev, V. (2010) Radionuclide molecular imaging using Affibody molecules. Curr. Pharm. Biotechnol. 11, 581-589.
6. Mume, E., Orlova, A., Larsson, B., Nilsson, A. S., Nilsson, F. Y., Sjöberg, S., and Tolmachev, V. (2005) Evaluation of ((4-hydroxyphenyl) ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjugate Chem. 16, 1547-1555. (Pubitemid 41683137)
7. Tolmachev, V., Mume, E., Sjöberg, S., Frejd, F. Y., and Orlova, A. (2009) Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur. J. Nucl. Med. Mol. Imaging 36, 692-701.
8. 18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 35, 1008-1018.
9. 18F]fluorobenzaldehyde via oxime chemistry. Mol. Imaging Biol. 10, 177-181.
10. 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J. Nucl. Med. 50, 781-789.
11. Ahlgren, S., Orlova, A., Rosik, D., Sandström, M., Sjöberg, A., Baastrup, B., Widmark, O., Fant, G., Feldwisch, J., and Tolmachev, V. (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjugate Chem. 19, 235-243. (Pubitemid 351213855)
12. Tolmachev, V., Xu, H.,Wållberg, H., Ahlgren, S., Hjertman, M., Sjöberg, A., Sandström, M., Abrahmsén, L., Brechbiel, M. W., and Orlova, A. (2008) Evaluation of a maleimido derivative of CHX-A00 DTPA for site-specific labeling of affibody molecules. Bioconjugate Chem. 19, 1579-1587.
13. EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur. J. Nucl. Med. Mol. Imaging 37, 613-622.
14. HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors. Mol. Imaging Biol. 12, 54-62.
15. 64Cu labeled affibody protein. Bioconjugate Chem. 21, 947-954.
16. 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol. Imaging Biol. 12, 316-324.
17. De León-Rodríguez, L. M., and Kovacs, Z. (2008) The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjugate Chem. 19, 391-402. (Pubitemid 351294908)
18. Anderson, C. J., Wadas, T. J., Wong, E. H., and Weisman, G. R. (2008) Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Q. J. Nucl. Med. Mol. Imaging 52, 185-192. (Pubitemid 351721939)
19. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc. Natl. Acad. Sci. U.S.A. 104, 12462-12467. (Pubitemid 47206160)
20. 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J. Nucl. Med. 48, 1327-1337. (Pubitemid 47242799)
21. Hausner, S. H., Kukis, D. L., Gagnon, M. K., Stanecki, C. E., Ferdani, R., Marshall, J. F., Anderson, C. J., and Sutcliffe, J. L. (2009) Evaluation of [(64)Cu]Cu-DOTA and [(64)Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alpha(v)beta (6)-specific peptide. Mol. Imaging 8, 111-121.
22. Tolmachev, V., and Orlova, A. (2010) Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. Curr. Med. Chem. 17, 2636-2655.
23. Clarke, E., and Martell, A, E. (1991) Stabilities of the Fe(III), Ga(III) and In(III) chelates of N,N',N''-triazacyclononanetriacetic acid. Inorg. Chim. Acta 181, 273-280.
24. Clarke, E. T., and Martell, A. E. (1992) Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13-, and 14-membered tetraazamacrocycles. Inorg. Chim. Acta 190, 37-46.
25. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjugate Chem. 13, 530-541. (Pubitemid 34535940)
26. 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J. Nucl. Med. 49, 830-836.
27. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur. J. Nucl. Med. Mol. Imaging 36, 947-957.
28. Velikyan, I., Maecke, H., and Langstrom, B. (2008) Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjugate Chem. 19, 569-573. (Pubitemid 351294931)
29. 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjugate Chem. 21, 1331-1340.
30. Craig, A. S., Helps, I. M., Parker, D., Adams, H., Bailey, N. A., Williams, M. G., Smith, J. M. A., and Ferguson, M. (1989) Crystal and molecular structure of a seven-coordinate chlorindium(III) complex of 1,4,7- triazacyclononanetetracetic acid. Polyhedron 8, 2481-2484.
31. Maeke, H., Scherer, G., Heppeler, A., and Henig, M. (2001) Is In-111 an ideal surrogate for Y-90? If not, why?. Eur. J. Nucl. Med. 28, 967.
32. 177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur. J. Nucl. Med. Mol. Imaging 32, 1457-1462. (Pubitemid 41746851)
33. HER2:342-pep2: implications for development of labeled tracers. Cancer Biother. Radiopharm. 23, 435-442.
34. Jones, K. L., and Buzdar, A. U. (2009) Evolving novel anti-HER2 strategies. Lancet Oncol. 10, 1179-1187.
35. Murphy, C. G., and Fornier, M. (2010) HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park) 24, 410-415.
36. Pienta, K. J., and Smith, D. C. (2005) Advances in prostate cancer chemotherapy: a new era begins. C.A. Cancer J. Clin. 55 300-318. (Pubitemid 41377334)
37. Agus, D. B., Scher, H. I., Higgins, B., Fox, W. D., Heller, G., Fazzari, M., Cordon-Cardo, C., and Golde, D. W. (1999) Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 59, 4761-4764. (Pubitemid 29472871)
38. Liu, Y., Majumder, S., McCall, W., Sartor, C. I., Mohler, J. L., Gregory, C. W., Earp, H. S., and Whang, Y. E. (2005) Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res. 65, 3404-3409. (Pubitemid 40524626)
39. Ziada, A., Barqawi, A., Glode, L.M., Varella-Garcia,M., Crighton, F., Majeski, S., Rosenblum,M., Kane,M., Chen, L., and Crawford, E. D. (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60, 332-337. (Pubitemid 39050653)
40. Lara, P. N., Jr., Chee, K. G., Longmate, J., Ruel, C., Meyers, F. J., Gray, C. R., Edwards, R. G., Gumerlock, P. H., Twardowski, P., Doroshow, J. H., and Gandara, D. R. (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100, 2125-2131. (Pubitemid 38580330)
41. Sridhar, S. S., Hotte, S. J., Chin, J. L., Hudes, G. R., Gregg, R., Trachtenberg, J., Wang, L., Tran-Thanh, D., Pham, N. A., Tsao, M. S., Hedley, D., Dancey, J. E., and Moore, M. J. (2010) A multicenter phase II clinical trial of Lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am. J. Clin. Oncol. 33, 609-613
42. Tolmachev, V. (2008) Imaging of HER-2 overexpression in tumors for guiding therapy. Curr. Pharm. 14, 2999-3019.
43. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J. Nucl. Med. 50, 417-425.
44. de Jong, M., Breeman, W. A., Bakker, W. H., Kooij, P. P., Bernard, B. F., Hofland, L. J., Visser, T. J., Srinivasan, A., Schmidt, M. A., Erion, J. L., Bugaj, J. E., Mäcke, H. R., and Krenning, E. P. (1998) Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 58, 437-441. (Pubitemid 28087403)
45. 111In-octreotide. J. Nucl. Med. 41, 1114-1119. (Pubitemid 30396667)
46. 3] Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. Proc. Assoc. Am. Physicians 111, 63-69. (Pubitemid 29047111)
47. 3]+, and show improved biodistribution. Bioconjugate Chem. 21, 2013-2022.
48. Reubi, J. C. (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24, 389-427. (Pubitemid 37056239)